Search results
Results from the WOW.Com Content Network
Prescient Therapeutics Ltd (Prescient) was created in 2014 by bringing together two small molecule drug assets from separate US private companies (Pathway Oncology for PTX-100 and AKTivate Therapeutics for PTX-200) into the existing ASX-listed shell company Virax Holdings Ltd (Virax).
Axicabtagene ciloleucel (KTE-C19, ZUMA-3, YESCARTA) was an investigational therapy (for the treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL)) in which a patient's T cells were genetically modified to express a chimeric antigen receptor designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias. [11]
In May 2015, the company announced its intention to acquire Stage Cell Therapeutics for up to $223 million. [6] Later in the same month the company launched a collaboration, with Editas Medicine, to create CAR-T and high-affinity T cell receptor therapies to treat cancer, with the potential to generate up to $737 million-plus for Editas. [7]
In November 2023, Legend Biotech and Novartis signed an out-license deal to develop and manufacture Legend's chimeric antigen receptor (CAR-T) therapies, that go after delta-like ligand protein 3 (DLL3) including large cell neuroendocrine carcinoma candidate LB2102. Novartis will pay the New-Jersey–based biotech $100 million upfront, and ...
In May 2019, the company announced an investment by Novo Holdings for a stake of 10.1% in OXB, totalling $55 million (USD) to develop its gene therapy technology. [6] The firm had already established collaborations with Sanofi, Novartis and other groups to provide lentiviral vector manufacturing.
A company’s dividend yield can be calculated by taking the annual dividend per share and dividing by the current stock price. Today, an S&P 500 index fund pays a dividend yield of about 1.3 percent.
As we move further into 2025, investors are scanning the markets for stocks that can help their portfolio profit. QuantumScape (NYSE: QS) can improve EV batteries in just about every way possible ...
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.